LIFE: Effect of F2695 on Functional Recovery After Ischemic Stroke

Sponsor
Pierre Fabre Medicament (Industry)
Overall Status
Completed
CT.gov ID
NCT01639014
Collaborator
(none)
532
87
2
31
6.1
0.2

Study Details

Study Description

Brief Summary

The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
532 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study
Study Start Date :
Jul 1, 2012
Actual Primary Completion Date :
Feb 1, 2015
Actual Study Completion Date :
Feb 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: F2695

Drug: F2695
75 mg OD in 2 capsules

Placebo Comparator: placebo

Drug: placebo
2 capsules

Outcome Measures

Primary Outcome Measures

  1. Percentage of patients with a Modified Rankin Scale (mRS) less than or equal to 1 at Week 12 [week 12]

Secondary Outcome Measures

  1. Percentage of patients with NIHSS score less than or equal to 5 at Week 12 [week 12]

  2. Percentage of patients with at least one moderate to severe depressive [Baseline to week 12]

  3. Change from baseline to Week 12 of the mean NIHSS total and motor scores [baseline to week 12]

  4. Safety and tolerability assessed by the investigator including SAEs, AEs, vital signs, ECG,physical examination and laboratory tests [baseline to week 12]

  5. Percentage of patients with a mRS score less than or equal to 2 at Week 12 [baseline to week 12]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female patient, 18 to 80 years of age

  • Confirmed acute ischemic stroke within the past 2 - 10 days

  • Unilateral motor deficit,

  • National Institutes of Health stroke scale (NIHSS) motor score >= 5

  • Modified Rankin Scale (mRS) of 4 or 5

  • Able and willing to comply with the site rehabilitation program requirements

Exclusion Criteria:
  • Aphasia

  • Severe post-stroke condition

  • Active depressive episode

  • Intra-cerebral hemorrhage

  • Use of anti-depressant drugs

  • Cardiac rhythm disorder

  • Uncontrolled arterial hypertension

  • Other severe acute or chronic medical or psychiatric condition.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cliniques Universitaires Saint Luc Brussels Belgium
2 Universitair Ziekenhuis Gent Ghent Belgium
3 Universitaire Ziekenhuis Gasthuisberg Leuven Belgium
4 Clinique Saint-Joseph Liege Belgium
5 Regional Ziekenhuis Sint-Trudo Sint-Truiden Belgium
6 Sint-Andriesziekenhuis Tielt Belgium
7 Academisch Ziekenhuis Sint Augustinus Wilrijk Belgium
8 Fakultní nemocnice u sv. Anny v Brne Brno Czech Republic
9 Fakultní nemocnice Hradec Králové Hradec Kralové Czech Republic
10 Litomyšlská Nemocnice, a.s. Litomyšl Czech Republic
11 Fakultní nemocnice Olomouc Olomouc Czech Republic
12 Vítkovická nemocnice a.s. Ostrava - Vítkovice Czech Republic
13 Fakultní Nemocnice Ostrava Ostrava Czech Republic
14 Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon Besançon France
15 Clinique des Cèdres Cornebarrieu France
16 Centre Hospitalier de Lens Lens France
17 Hôpital Roger Salengro Lille France
18 Groupe Hospitalier Paris Saint Joseph Paris France
19 Hopital Lariboisière Paris France
20 Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie Poitiers France
21 Centre Hospitalier Universitaire de Saint Etienne, Hôpital Nord Saint Priest en Jarez France
22 Hôpital Purpan Toulouse France
23 Neurologische Klinik GmbH Bad Neustadt/Saale Germany
24 Universitätsklinik Charité, Campus Mitte Berlin Germany
25 Universitätsklinikum Bonn Bonn Germany
26 Universitätsklinikum Erlangen Erlangen Germany
27 Universitätsklinikum Essen Essen Germany
28 Freiburger Universitätsklinik Freiburg Germany
29 Asklepios Klinik Altona Hamburg Germany
30 Universitätsklinikum Leipzig Leipzig Germany
31 Universitätsklinikum Münster Münster Germany
32 Asklepios Fachklinikum Teupitz Teupitz Germany
33 Jahn Ferenc Dél-pesti Kórház Budapest Hungary
34 Magyar Honvédség Honvédkórház Budapest Hungary
35 Semmelweis Egyetem Neurológiai Klinika Budapest Hungary
36 Debreceni Egyetem Orvos- és Egészségtudományi Centrum Debrecen Hungary
37 Petz Aladár Megyei Oktató Kórház Gyor Hungary
38 Kaposi Mór Megyei Oktató Kórhaz Kaposvár Hungary
39 BAZ Megyei és Egyetemi Oktató Kórház Miskolc Hungary
40 Kanizsai Dorottya Kórház Nagykanizsa Hungary
41 Jósa András Oktató Kórház Nyíregyháza Hungary
42 Soproni Erzsébet Oktató Kórház Sopron Hungary
43 Fejér Megyei Szent György Kórház Székesfehérvár Hungary
44 Azienda Sanitaria Ospedaliera "San Giovanni Battista" Foligno Italy
45 Azienda Ospedaliera San Gerardo Monza Italy
46 IRCCS "Istituto Neurologico C. Mondino" Pavia Italy
47 Ospedale Santa Maria della Misericordia Perugia Italy
48 IRCCS Fondazione Santa Lucia Roma Italy
49 Istituto Clinico Humanitas Rozzano Italy
50 Hospital Garcia de Orta Almada Portugal
51 Hospitais da Universidade de Coimbra Coimbra Portugal
52 Hospital de Santa Maria Lisboa Portugal
53 Centro Hospitalar do Porto / Hospital Geral de Santo António Porto Portugal
54 Hospital de São João Porto Portugal
55 Municipal Healthcare Institution "Municipal Clinical Hospital # 3" Chelyabinsk Russian Federation
56 Regional Hospital #1, Ekaterinburg Ekaterinburg Russian Federation
57 Professor S.V. Ochapovsky Territorial Clinical Hospital #1 Krasnodar Russian Federation
58 Clinical Hospital Number 31 Moscow Russian Federation
59 Non-state Healthcare Institution "N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway Moscow Russian Federation
60 Scientific Research Neurology Institute of Russian Academy of Medical Services Moscow Russian Federation
61 State Budget Healthcare Institution "City clinical hospital #20" Moscow Russian Federation
62 State Institution of Healthcare of Moscow City "City Clinical Hospital #61" Moscow Russian Federation
63 State Institution "Saint Petersburg I.I. Dzhanelidze Research Institute of Emergency" Petersburg Saint Russian Federation
64 Municipal Medical Institute "N.I.Pirogov City Clinical hospital #1" Samara Russian Federation
65 State Healthcare Institution "Samara M.I.Kalinin Regional Clinical Hospital" Samara Russian Federation
66 Smolensk State Medical Academy of RosZdrav Smolensk Russian Federation
67 Bashkirian State Medical University Ufa Russian Federation
68 Hospital General de Albacete Albacete Spain
69 Hospital Universitari Germans Trias i Pujol Badalona Spain
70 Hospital Santa Creu i Sant Pau Barcelona Spain
71 Hospital Universitari Vall d'Hebron Barcelona Spain
72 Hospital Universitario de Girona Doctor Josep Trueta Gerona Spain
73 Hospital Clínico San Carlos Madrid Spain
74 Hospital Universitario La Princesa Madrid Spain
75 Hospital Universitario Ramón y Cajal Madrid Spain
76 Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela Spain
77 Hospital de Tortosa Verge de la Cinta Tortosa Spain
78 Hospital Clinico Universitario de Valladolid Valladolid Spain
79 Danderyds Sjukhus AB Danderyd Sweden
80 Sahlgrenska Universitetsjukhuset Göteborg Sweden
81 Universitetssjukhuset Linköping Linköping Sweden
82 Skånes Universitetssjukhus i Lund Lund Sweden
83 Mora lasarett Mora Sweden
84 Kärnsjukhuset i Skövde-KSS Skövde Sweden
85 Universitätsspital Basel Basel Switzerland
86 Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
87 Klinik Hirslanden Zürich Switzerland

Sponsors and Collaborators

  • Pierre Fabre Medicament

Investigators

  • Principal Investigator: François Chollet, Hôpital Purpan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pierre Fabre Medicament
ClinicalTrials.gov Identifier:
NCT01639014
Other Study ID Numbers:
  • F02695 LP 2 05
  • 2012-001592-37
First Posted:
Jul 12, 2012
Last Update Posted:
Apr 1, 2015
Last Verified:
Mar 1, 2014
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2015